Autoimmune Hepatitis Market

Market Overview:

The 7 major autoimmune hepatitis markets reached a value of US$ 115.3 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 156.9 Million by 2034, exhibiting a growth rate (CAGR) of 2.84% during 2024-2034.

The autoimmune hepatitis market has been comprehensively analyzed in IMARC's new report titled "Autoimmune Hepatitis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Autoimmune hepatitis refers to a chronic inflammatory liver disease characterized by the immune system disrupting healthy liver cells, leading to liver inflammation and potential long-term damage. The symptoms of this ailment can vary in intensity and may include fatigue, jaundice (yellowing of the skin and eyes), abdominal discomfort, loss of appetite, unexplained weight loss, etc. In some cases, individuals suffering from the illness might experience joint pain, skin rashes, or enlargement of the liver and spleen. The diagnosis of autoimmune hepatitis involves a comprehensive approach that includes a thorough medical history assessment, a physical examination, blood tests to measure liver enzyme levels, and the detection of specific autoantibodies associated with the disease. Additionally, the healthcare provider may also perform imaging studies like ultrasound or magnetic resonance imaging to determine liver damage or rule out various other hepatic conditions. Prompt diagnosis and early intervention are important in managing this disorder to prevent complications, such as cirrhosis and liver failure.

The escalating prevalence of immune-mediated syndrome, in which the body's immune system malfunctions and targets its own liver tissues, leading to progressive liver damage, is primarily driving the autoimmune hepatitis market. In addition to this, the rising demand for liver transplantation as a viable treatment alternative for end-stage disease conditions, where conventional therapies prove ineffective, is also creating a positive outlook for the market. Moreover, the widespread adoption of immunosuppressive drugs, such as corticosteroids, azathioprine, mycophenolate mofetil, etc., to suppress the overactive immune response and reduce liver inflammation in individuals suffering from the disorder is further bolstering the market growth. Apart from this, the increasing awareness among healthcare professionals and the general population about the importance of early detection and timely management of the ailment is acting as another significant growth-inducing factor. Additionally, the emerging popularity of plasmapheresis techniques, owing to their various advantages, like rapid removal of harmful antibodies, faster recovery, symptom relief, etc., is also augmenting the market growth. Furthermore, the inflating application of biologics, such as anti-TNF agents and anti-CD20 monoclonal antibodies, which work by targeting certain components of the immune system in patients, is expected to drive the autoimmune hepatitis market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the autoimmune hepatitis market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for autoimmune hepatitis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the autoimmune hepatitis market in any manner.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034
   

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the autoimmune hepatitis market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the autoimmune hepatitis market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current autoimmune hepatitis marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the autoimmune hepatitis market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the autoimmune hepatitis market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the autoimmune hepatitis market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of autoimmune hepatitis across the seven major markets?
• What is the number of prevalent cases (2018-2034) of autoimmune hepatitis by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of autoimmune hepatitis by gender across the seven major markets?
• How many patients are diagnosed (2018-2034) with autoimmune hepatitis across the seven major markets?
• What is the size of the autoimmune hepatitis patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of autoimmune hepatitis?
• What will be the growth rate of patients across the seven major markets?
   

Autoimmune Hepatitis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for autoimmune hepatitis drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the autoimmune hepatitis market?
• What are the key regulatory events related to the autoimmune hepatitis market?
• What is the structure of clinical trial landscape by status related to the autoimmune hepatitis market?
• What is the structure of clinical trial landscape by phase related to the autoimmune hepatitis market?
• What is the structure of clinical trial landscape by route of administration related to the autoimmune hepatitis market?